Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Kjell Öberg(Uppsala University Hospital), S. Jelić(Oncology Institute of Vojvodina), Per Hellman(Uppsala University Hospital), Dik J. Kwekkeboom(Erasmus MC)
Cited by 82
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951